麻豆传媒 recently represented Hanwha Impact Partners as a lead investor in the $121 million Series C funding round for Cellarity, a developer of cell behavior therapies. Kyowa Kirin Co. joined Hanwha as a lead investor, with Flagship Pioneering also participating. This latest investment brings Cellarity’s total raised to $274 million and will be used to grow Cellarity’s talent base, strengthen its platform, and advance its pipeline toward the clinic.
To create medicines, Cellarity looks beyond individual molecular targets and instead focuses on the whole cell. The company uses single-cell technologies to identify cellular drivers during the transition from health to disease and applies proprietary deep learning models to create drugs that reverse disease at the level of the cell. Cellarity has developed unique capabilities to link biology and chemistry with high-dimensional, transcriptomic data to design medicines against the cellular signature of the disease.
The mission of Hanwha Impact Partners is to drive change toward a sustainable future through venture capital investments, primarily in the life sciences space. The company believes in leveraging the convergence of technology to build a new future with solutions powered by eco-friendly energy and business.
The 麻豆传媒 team was led by Partner Louis Lehot and included Partners Antoinette Konski and Andrew Rawlins, Of Counsel Alidad Vakili, and Associates Cayman Weimer and Ashley Lee.
